PU
Therapeutic Areas
BioNTech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BNT327 | Advanced solid tumors | Phase 2/3 |
| BNT116 | Non-small cell lung cancer (NSCLC) | Phase 2 |
| BNT122 (autogene cevumeran) | Adjuvant pancreatic cancer, melanoma | Phase 2 |
| BNT113 | HPV16+ head and neck cancer | Phase 2/3 |
| BNT311 (GEN1046) | Advanced solid tumors | Phase 2 |
| BNT312 (GEN1053) | Advanced solid tumors | Phase 1/2 |
| BNT211 | CLDN6+ advanced solid tumors | Phase 1/2 |
| BNT323 (DB-1303) | HER2-expressing solid tumors | Phase 3 |
Leadership Team at BioNTech
PÖ
Prof. Özlem Türeci, M.D.
Chief Medical Officer
PC
Prof. Christoph Huber, M.D.
Co-founder, Scientific Advisory Board Chair
JH
Jens Holstein, CPA
Chief Financial Officer
SM
Sean Marett, MBA
Chief Business and Commercial Officer
SP
Sierk Poetting, Ph.D.
Chief Operating Officer